Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) EBT (2021 - 2023)

Historic EBT for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$39.7 million.

  • Cullinan Therapeutics' EBT fell 3710.01% to -$39.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$169.2 million, marking a year-over-year decrease of 21183.42%. This contributed to the annual value of -$167.5 million for FY2024, which is 104.3% up from last year.
  • Per Cullinan Therapeutics' latest filing, its EBT stood at -$39.7 million for Q4 2023, which was down 3710.01% from -$39.2 million recorded in Q3 2023.
  • In the past 5 years, Cullinan Therapeutics' EBT ranged from a high of $240.1 million in Q2 2022 and a low of -$58.1 million during Q1 2023
  • For the 3-year period, Cullinan Therapeutics' EBT averaged around -$7.1 million, with its median value being -$30.6 million (2022).
  • The largest annual percentage gain for Cullinan Therapeutics' EBT in the last 5 years was 156076.4% (2022), contrasted with its biggest fall of 238752.64% (2022).
  • Cullinan Therapeutics' EBT (Quarter) stood at -$34.2 million in 2021, then rose by 15.38% to -$28.9 million in 2022, then tumbled by 37.1% to -$39.7 million in 2023.
  • Its EBT stands at -$39.7 million for Q4 2023, versus -$39.2 million for Q3 2023 and -$32.2 million for Q2 2023.